Proving the Business Case for the Internet of Things

Fitbit and Medtronic partner to tackle diabetes

Steve Rogerson
December 20, 2016
 
Fitness wearables company Fitbit is partnering with Dublin-based Medtronic to integrate health and activity tracking for patients living with diabetes and their physicians and care teams.
 
The iPro2 MyLog mobile app will let patients living with type-two diabetes see their glucose levels and physical activity data in one streamlined application.
 
The integration and partnership brings together Medtronic's medical technology with the convenience of automatic activity tracking from Fitbit, which provides meaningful insights into how exercise impacts glucose levels for more effective diabetes care management.
 
"We believe monitoring glucose is a critical element in the management of diabetes and therefore glucose should be included among other vital signs," said Laura Stoltenberg, vice president and general manager of non-intensive diabetes therapies at Medtronic. “As such, it has never been more important to increase the collaboration between healthcare and technology to simplify daily diabetes management for the 29 million patients living with type-two diabetes in the United States.”
 
By creating a connection between physical activity and glucose levels, the mobile app provides tools and insights so physicians can optimise therapy and patients can better understand how to manage their diabetes.
 
“By helping people with diabetes implement lasting lifestyle changes, this partnership underscores our commitment to transforming diabetes care, together, for greater freedom and better health," said Stoltenberg.
 
Maintaining and tracking glucose levels is critical to managing diabetes effectively. For people living with type-two diabetes, understanding how exercise affects glucose levels is a critical element to proper glucose management and long-term health. Additionally, many patients are manually tracking and recording their physical activity, requiring them to recall and communicate that information to their physician from memory.
 
The iPro2 MyLog mobile app will allow type-two diabetes patients to combine data generated by their Fitbit activity tracker and Medtronic's iPro2 professional CGM system, eliminating the need to enter physical activity data manually, and providing an understanding of how exercise impacts glucose levels. MyLog will simplify the sharing of information with a patient's healthcare team, facilitating productive discussions about care and the benefits of exercise on diabetes management.
 
"We believe the integration of wearable technology with professional diagnostic tools can provide a more accurate and actionable view of a patient's physical activity," said Adam Pellegrini, vice president of digital health for Fitbit. "By partnering with Medtronic, we are able to bring the power of Fitbit's automatic activity tracking together with continuous glucose monitoring, allowing patients and providers to have a more informed conversation."
 
Like heart monitors and other clinical trackers, the iPro2 Professional CGM system records a patient's glucose levels 24 hours a day for up to six days. Used intermittently, the system provides physicians and the health care team with insights into how the nutrition plan, medication regimen and daily activities affect glucose levels of people with diabetes, enabling them to know more about their patients' glucose profile in less time and helping them make more informed decisions regarding diabetes management.
 
Sharing insights enables patients to understand the relationship between their glucose levels and lifestyle choices. In addition, the system delivers decision support for diabetes care providers through an algorithm-based, one-page pattern snapshot report that enhances their ability to identify and address key problem areas.
 
The MyLog mobile app displays glucose and sensor data captured by the iPro2 CGM device and can integrate physical activity data collected from a patient's Fitbit activity tracker. The integration of these sets of data means patients will no longer need to use a paper log sheet to record daily activity related to glucose readings, medication adherence, diet and exercise.
 
This provides established and newly diagnosed type-two diabetes patients and their physicians with a more comprehensive look at how certain behaviour, such as exercise and diet choices, affects glucose levels during physician supervised six-day diagnostic periods. Results can inform provider's therapy and lifestyle recommendations that can lead to improved glucose control and educate patients on how certain behaviour can cause hypoglycemic and hyperglycemic episodes.
 
MyLog is available for Android and iOS smartphones for patients undergoing evaluation with Medtronic's iPro2 professional CGM system.